Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation
NCT02861417Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2016
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of busulfan and cyclophosphamide in hematologic malignancy (6 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Non-relapse mortality rate at 100 days. Started Aug 2016; status: active, not recruiting.
02
Drugs
busulfancyclophosphamide
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02861417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02861417.